Common laboratory parameters as predictors of prognosis in primary lung cancer.
[BACKGROUND] The prognosis of patients with primary lung cancer remains poor.
- 표본수 (n) 915
- 95% CI 0.690-0.764
APA
Cai M, Chen H, et al. (2025). Common laboratory parameters as predictors of prognosis in primary lung cancer.. Frontiers in oncology, 15, 1708848. https://doi.org/10.3389/fonc.2025.1708848
MLA
Cai M, et al.. "Common laboratory parameters as predictors of prognosis in primary lung cancer.." Frontiers in oncology, vol. 15, 2025, pp. 1708848.
PMID
41602400
Abstract
[BACKGROUND] The prognosis of patients with primary lung cancer remains poor. Therefore, this study aimed to develop and validate a predictive model to evaluate the overall survival (OS) of these patients.
[METHODS] A retrospective analysis was conducted on the data of 1,308 patients with primary lung cancer who received treatment and follow-up at our hospital from 2016 to 2022. The entire cohort was randomly divided into a derivation cohort (70%, n=915) and a validation cohort (30%, n=393) in a 7:3 ratio. A prognostic nomogram was constructed using Cox-least absolute shrinkage and selection operator regression analysis to predict the OS probabilities at 1-, 3-, and 5-years. Kaplan-Meier curve and log-rank tests were used to analyze and compare OS among different patient subgroups. The model was comprehensively evaluated through the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).
[RESULTS] Age, gender, red blood cell count, serum potassium, albumin-globulin ratio, and prothrombin time activity were the prognostic indicators for predicting OS in patients with primary lung cancer. In the derivation cohort, the AUCs at 1-, 3-, and 5-years were 0.739 (95% confidence interval [CI]: 0.702-0.776), 0.727 (95% CI: 0.690-0.764), and 0.675 (95% CI: 0.629-0.721). In the validation cohort, the AUCs at 1-, 3-, and 5-years were 0.770 (95% CI: 0.712-0.827), 0.784 (95% CI: 0.732-0.837), and 0.717 (95% CI: 0.646-0.789), respectively. The calibration curve and DCA results confirmed the model's good predictive power.
[CONCLUSION] In this study, we developed and validated an OS prediction model for patients with primary lung cancer. Providing personalized predictions with multiple outcomes increases the information available to patients and clinicians.
[METHODS] A retrospective analysis was conducted on the data of 1,308 patients with primary lung cancer who received treatment and follow-up at our hospital from 2016 to 2022. The entire cohort was randomly divided into a derivation cohort (70%, n=915) and a validation cohort (30%, n=393) in a 7:3 ratio. A prognostic nomogram was constructed using Cox-least absolute shrinkage and selection operator regression analysis to predict the OS probabilities at 1-, 3-, and 5-years. Kaplan-Meier curve and log-rank tests were used to analyze and compare OS among different patient subgroups. The model was comprehensively evaluated through the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).
[RESULTS] Age, gender, red blood cell count, serum potassium, albumin-globulin ratio, and prothrombin time activity were the prognostic indicators for predicting OS in patients with primary lung cancer. In the derivation cohort, the AUCs at 1-, 3-, and 5-years were 0.739 (95% confidence interval [CI]: 0.702-0.776), 0.727 (95% CI: 0.690-0.764), and 0.675 (95% CI: 0.629-0.721). In the validation cohort, the AUCs at 1-, 3-, and 5-years were 0.770 (95% CI: 0.712-0.827), 0.784 (95% CI: 0.732-0.837), and 0.717 (95% CI: 0.646-0.789), respectively. The calibration curve and DCA results confirmed the model's good predictive power.
[CONCLUSION] In this study, we developed and validated an OS prediction model for patients with primary lung cancer. Providing personalized predictions with multiple outcomes increases the information available to patients and clinicians.
같은 제1저자의 인용 많은 논문 (5)
- Breaking barriers: epithelial-mesenchymal transition role in melanoma invasion and resistance.
- Rational Design and Responsive Transdermal Cargo Delivery of Microneedles in the Treatment of Melanoma.
- Tumor-derived RAC1 mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor.
- Symptom clusters of patients with advanced thyroid cancer: a cross-sectional study.
- Identification and validation of calcium signaling pathway-related biomarkers in T1 and T2 lymph node metastatic gastric cancer.